Fetal exposure to DES results in de-regulation of Wnt7a during uterine morphogenesis

Diethylstilbestrol (DES) was used in the United States from 1947 to 1971 to prevent miscarriage. Approximately one-million women were exposed in utero to DES (ref. 1). Women prenatally exposed to DES commonly display epithelial and/or structural changes in the uterus, cervix, or vagina, and can develop clear cell adenocarcinoma of the vagina or cervix at an early age2–5. The frequency of DES-associated reproductive tract anomalies6 and cancer7 appears temporally related to the time of exposure, with most abnormal findings occurring in women exposed to DES in the first trimester. The specific molecular response to DES that fully accounts for the DES syndrome remains unknown. We recently reported that mice lacking Wnt7a have malformed female reproductive tracts8 (FRTs). The observed phenotype closely resembles the reproductive tract morphologies observed in female mice prenatally exposed to DES (ref. 9), and indicates that Wnt7a may have a role in the DES response in the developing FRT. To directly compare the effects of loss of Wnt7a with the effects of DES in the FRT, we generated mice with DES-induced malformed FRTs using an established protocol9,10. DES-exposed mice had shallow vaginal fornices, malformed oviducts that lacked coils, Wolffian duct remnants (Fig. 1a), vaginal concretions and adenotic lesions in the vagina9,11,12. Wnt7a−/− mice also had shallow vaginal fornices (data not shown) and malformed oviducts8. Similarly, Wnt7a−/− FRTs contained Wolffian duct remnants (Fig. 1b), vaginal concretions (Fig. 1c) and epithelial inclusions in the vaginal stroma (Fig. 1d). Control FRTs (oil treated) had normal morphology and tissue cytoarchitecture (Fig. 1e). DES-exposed and Wnt7a−/− FRTs displayed stratified epithelium with reduced stroma and glands (Fig. 1f,g). DES-exposed women were reported to display uterine abnormalities which were attributed to abnormal smooth muscle proliferation13. Both Wnt7a−/− and DES-exposed mice had a disorganized and thickened inner layer of smooth muscle (Fig. 1i–k). Fig. 1 Prenatal DES treatment mimics the phenotype of the Wnt7a−/− female reproductive tract. Pregnant CD-1 mice were treated with 200 μg/day of DES (Sigma) suspended in sesame oil, or with oil alone, on days 15–18 of gestation ... Wnt7a is normally expressed perinatally in the luminal epithelium of the uterus8. As expected, Wnt7a was found to be expressed in the epithelium of the control uterus (Fig.2 b,d). In the DES-exposed uteri, however, low levels of Wnt7a transcripts were detected at birth (Fig. 2f). Wnt7a expression in the DES-exposed uteri returned to high levels five days after birth (Fig. 2h) and was maintained at later stages (data not shown). Fig. 2 Wnt7a expression is downregulated in DES-exposed mice at the time of birth. The photomicrographs show phase (a,c,e,g) and dark-field images (b,d,f,h) of control and DES-exposed uteri at birth and at 5 days postnatal examining Wnt7a expression. Wnt7a is ... Previous studies have shown that cytodifferentiation of the female reproductive tract in mice is determined 5–7 days after birth and is dependent on mesenchymal-epithelial interactions14. After this time period, the uterine epithelium is no longer responsive to inductive signals from vaginal stroma15. Thus, the FRT has a critical temporal window during which key patterning events occur. We propose that the observed downregulation of Wnt7a during this critical window is sufficient to account for the mouse DES syndrome. DES-like substances such as tamoxifen have recently been shown to be effective in decreasing the incidence of breast cancer in premenopausal women, although uterine cancer increases twofold (NCI clinical trials web site, http://cancertrials.nci.nih.gov). Understanding the molecular responses in breast and uterine tissues to steroidal pharmacological agents will be of high importance should their use increase in clinical applications.